Medaphor Group PLC Medaphor expands ScanNav AI pilot
23 July 2018 - 4:00PM
RNS Non-Regulatory
TIDMMED
Medaphor Group PLC
23 July 2018
MedaPhor Group plc
("MedaPhor" or the "Group")
Expands ScanNav AI pilot
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces that it has expanded the
pilot of its ScanNav artificial intelligence ("AI") image analysis
software into its second UK hospital, at the Princess Anne Wing
Ultrasound Department of the Royal United Hospitals ("RUH"),
Bath.
ScanNav is the first CE marked AI system to carry out an
automated, real-time "peer review" of obstetric ultrasound images
as the patient is scanned.
Initially targeted at the UK pregnancy screening programme,
offered to all women at approximately 20 weeks of pregnancy,
ScanNav uses deep-learning to evaluate over 50 individual criteria
to verify that the six views required by the NHS Fetal Anomaly
Screening Programme are complete and fit for purpose.
Commenting on their interest in ScanNav, Pam Norbury, Lead
Sonographer at RUH, said: "I am excited to be involved in this
pilot. We expect ScanNav will boost the confidence of trainees and
the newly qualified as they learn but also provide assurance to the
whole team that their image quality is of the standard expected in
this department. I am looking forward to increased clinical
capacity without loss of vital audit data & reduced image
storage on the digital archive system".
Commenting on the evaluation, Nick Sleep, Chief Technology
Officer of MedaPhor, said: "Our aim is to develop software tools to
guide and support clinicians in their use of ultrasound. The
feedback from our first pilot is that ScanNav is doing this and we
look forward to confirming this with Pam and her team. Their
enthusiasm for the technology mirrors ours and we are delighted to
be working them to bring this exciting software to market."
For more information about MedaPhor's clinical products
currently in development visit www.intelligentultrasound.com
-ends-
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Ian Whittaker, COO
Cenkos Securities Tel: +44 (0)20 7397 8900
Camilla Hume (Nominated Advisor)
Michael Johnson / Julian Morse (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com
Anna Dunphy / Paul Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541
McManus 893
About MedaPhor (www.investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops artificial intelligence-based clinical
image analysis software tools, augmented reality-based needle
guidance software and advanced hi-fidelity haptic and manikin-based
training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK, Atlanta in the US and
Hong Kong in Asia, MedaPhor operates two divisions:
Intelligent Ultrasound Simulation Division
Focuses on hi-fidelity ultrasound education and training through
simulation. Its three main products are the ScanTrainer OBGYN and
General Medical simulator training platform, the HeartWorks
echocardiography simulator platform and the BodyWorks Eve Point of
Care and Emergency Medicine Simulator. Over 500 MedaPhor simulators
have been sold to over 300 medical institutions in over 30
countries around the world.
Intelligent Ultrasound Clinical Division
Focuses on augmented reality and deep-learning based algorithms
to make ultrasound machines smarter and more accessible. Products
in development include ScanNav and NeedleGuide. ScanNav uses
machine-learning based algorithms to automatically identify, grade
and capture good ultrasound images. NeedleGuide aims to simplify
ultrasound-guided needling by using deep learning and augmented
reality to provide the user with pathway guidance and automated
tracking for a range of medical procedures.
Some products in the pipeline may require US FDA approval, as
such this material should be considered informational only and does
not constitute an offer to sell or infer claims or benefits.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAURVORWKABUAR
(END) Dow Jones Newswires
July 23, 2018 02:00 ET (06:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024